Citations

Showing 10 of 108104 citations.

Analysis of Fixed and Variable Operating Room (OR) Time Point Efficiency in Partial Nephrectomies: Open Versus Robotic-assisted
Geldmaker, Laura , Hasse, Christopher H., Baird, Bryce , Ericson, Christian , Haehn, Daniela A. , Anyane-Yeboah, Abena N., Wieczorek, Mikolaj A. , Ball, Colleen T. , Pak, Raymond W., Thiel, David D. , Myers, Amanda A. , Lyon, Timothy D.

Mayo Clinic

No container title available | April 25, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1577467/v1 Get It

Abstract Objective: To analyze operating room (OR) efficiency by evaluating fixed and variable OR times for open (OPN) and robotic-assisted partial nephrectomies (RAPN).Methods: We analyzed consecutive OPN and RAPN performed by one surgeon over a 24-month period. All patients were placed in the lateral decubitus position and secured with a beanbag regardless of approach. Fixed (nonprocedural) OR times were prospectively collected and defined as: in room to anesthesia release time (IRAT), anesthesia release to cut time (ARCT), and close to wheels out time (CTWO). Variable OR time was procedural cut to close time (CTCT). Comparison of fixed and variable OR time points between OPN and RAPN were performed using the Wilcoxon rank sum test. Results: 146 RAPN and 31 OPN were evaluated from 2019-2020. Median IRAT was similar for RAPN versus OPN [20 min (IQR: 16-25) vs. 20 min (IQR: 16-26), P=0.57]. Median ARCT was longer for RAPN than it was for OPN [40 min (IQR: 36-46) vs. 34 min (IQR: 30-39), P<0.001]. Median CTWO was similar for OPN (12 min, IQR: 9-14) and RAPN (11 min, IQR: 7-15) (P=0.89). Median CTCT was longer for RAPN (202 min, IQR: 170-236) compared to OPN (164 min, IQR: 154-184) (P<0.001).Conclusions: In a single surgeon partial nephrectomy series with the same patient positioning, utilization of robotic technology was associated with longer surgeon operating time as well as less efficient fixed OR times, specifically ARCT.
European Neuroendocrine Tumor Society ( ENETS ) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease
Grozinsky‐Glasberg, Simona , Davar, Joseph, Hofland, Johannes , Dobson, Rebecca , Prasad, Vikas , Pascher, Andreas , Denecke, Timm , Tesselaar, Margot , Panzuto, Francesco , Albåge, Anders , Connolly, Heidi M. , Riechelmann, Rachel P. , Toumpanakis, Christos , Grozinsky-Glasberg, Simona , Hofland, Johannes , Riechelmann, Rachel , Obadia, Jean‐François , Prasad, Vikas

Mayo Clinic

Journal of Neuroendocrinology | April 25, 2022 | Volume: 34 | Issue: 7 | Pages: No page available

10.1111/jne.13146 | PMID 35613326 Get It

Guideline to Practice: Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline
Shaheen, Nicholas J. , Iyer, Prasad G. , Souza, Rhonda F. , Wani, Sachin , Falk, Gary W.

Mayo Clinic

American Journal of Gastroenterology | April 25, 2022 | Volume: 117 | Issue: 8 | Pages: 1177-1180

10.14309/ajg.0000000000001788 | PMID 35467555 Get It

Transverse relaxation in fixed tissue: Influence of temperature and resolution on image contrast in magnetic resonance microscopy
Meloche, Ryan , Vučković, Ivan , Mishra, Prasanna K. , Macura, Slobodan , Meloche, Ryan , Mishra, Prasanna K. , Macura, Slobodan I , Vuckovic, Ivan

Mayo Clinic

NMR in Biomedicine | April 25, 2022 | Volume: 35 | Issue: 9 | Pages: No page available

10.1002/nbm.4747 | PMID 35467776 Get It

To describe transverse relaxation of water in fixed tissue, we propose a model of transverse relaxation accelerated by diffusion and exchange (TRADE) that assumes exchange between free (visible) and bound (invisible) water, which relax by the dipole–dipole interaction, chemical exchange, and translation in the field gradient. Depending on the prevailing mechanism, transverse relaxation time (T2) of water in fixed tissue could increase (when dipole–dipole interaction prevails) or decrease with temperature (when diffusion in the field gradient prevails). Chemical exchange can make T2 even temperature independent. Also, variation of resolution from 100 to 15 μm/pxl (or less) affects effective transverse relaxation. T2 steadily decreases with increased resolution ( , is the read direction resolution). TRADE can describe all of these observations (semi)quantitatively. The model has been experimentally verified on water phantoms and on formalin‐fixed zebrafish, mouse brain, and rabbit larynx tissues. TRADE could help predict optimal scanning parameters for high‐resolution MRM from much faster measurements at lower resolution.
Evaluating the clinical utility of the patient‐identified most bothersome symptom measure from PROMISE‐2 for research in migraine prevention
Dodick, David W. , McGinley, James S., Kymes, Steve, Østerberg, Ole, Cady, Roger , Buse, Dawn C. , Dodick, David W , Ashina, Messoud , Lipton, Richard B. , Goadsby, Peter J. , Houts, Carrie R. , Wirth, Robert J. , Ettrup, Anders , Ashina, Messoud

Mayo Clinic

Headache: The Journal of Head and Face Pain | April 25, 2022 | Volume: 62 | Issue: 6 | Pages: 690-699

10.1111/head.14295 | PMID 35466430 Get It

Abstract Objective To assess the utility of the novel patient‐identified (PI) most bothersome symptom (MBS) measure from PROMISE‐2, a phase 3 trial of eptinezumab for the preventive treatment of chronic migraine. Background Relief of bothersome migraine symptoms can influence satisfaction with treatment and therapeutic persistence. Understanding the impact of preventive treatment on a PI‐MBS could improve clinical decision‐making. Methods In PROMISE‐2, patients with chronic migraine received eptinezumab 100, 300 mg, or placebo administered intravenously every 12 weeks for up to 2 doses ( n = 1072). PI‐MBS was an exploratory outcome requiring each patient to self‐report their MBS in response to an open‐ended question. At baseline and week 12, patients rated overall improvement in PI‐MBS. The relationships among PI‐MBS at week 12 and change in monthly migraine days (MMDs) from baseline to month 3 (weeks 9–12), Patient Global Impression of Change at week 12, and changes from baseline to week 12 in the 6‐item Headache Impact Test total, EuroQol 5‐dimensions 5‐levels visual analog scale, and 36‐item Short‐Form Health Survey component scores were assessed. Results Treatment groups had similar baseline characteristics and reported a total of 23 unique PI‐MBS, most commonly light sensitivity (200/1072, 18.7%), nausea/vomiting (162/1072, 15.1%), and pain with activity (147/1072, 13.7%). Improvements in PI‐MBS at week 12 correlated with changes in MMDs ( ρ = −0.49; p < 0.0001) and other patient‐reported outcomes. Controlling for changes in MMDs, PI‐MBS improvement predicted other patient‐reported outcomes in expected directions. The magnitude of the standardized mean differences between placebo and active treatment for PI‐MBS were 0.31 ( p < 0.0001 vs. placebo) and 0.54 ( p < 0.0001 vs. placebo) for eptinezumab 100 and 300 mg, respectively. Conclusions Improvement in PI‐MBS at week 12 was associated with improvement in other patient‐reported outcome measures, and PI‐MBS may be an important patient‐centered measure of treatment benefits in patients with chronic migraine.
New Methodology for Accurate Determination of Molecular Co-localization at the Nanoscale
Verkhoturov, Dmitriy S., Eller, Michael J. , Han, Yong Duk, Верхотуров, С. В., Revzin, Alexander , Eller, Michael J , Schweikert, Emile A , Crulhas, Bruno P.

Mayo Clinic

Langmuir | April 25, 2022 | Volume: 38 | Issue: 18 | Pages: 5626-5632

10.1021/acs.langmuir.2c00217 | PMID 35465673 Get It

Controversies in Acute Stroke Treatment
Brethour, Mary, Nyström, Karin , Broughton, Sandra S., Kiernan, Terri E, Perez, Amy, Handler, Diane, Swatzell, Victoria, Yang, Joanna Jiehong, Starr, Michele, Seagraves, Karen B., Cudlip, Fern, Biby, Sharon , Tocco, Susan, Owens, Pauline, Alexandrov, Anne W. , Broughton, Sandra, Kiernan, Terri-Ellen J.

Mayo Clinic

AACN Advanced Critical Care | April 25, 2022 | Volume: 23 | Issue: 2 | Pages: 158-172

10.4037/nci.0b013e31824fe1b6 Get It

The evidence base supporting the management of patients with acute stroke is evolving at a rapid rate, as new methods that aim to reduce disability and death from stroke are explored. Intravenous tissue plasminogen activator remains the only treatment shown in numerous studies to reduce disability 3 months after stroke with no increase in the risk of death and a relatively minor rate of symptomatic intracerebral hemorrhage complications. Despite these findings, health care providers have been slow to adopt this evidence-based treatment, which results in many patients experiencing disability caused by stroke. Numerous controversies exist related to the management of patients with acute stroke, including the use of tissue plasminogen activator, positioning and early mobility, blood pressure lowering in acute intracerebral hemorrhage, and even the use of innovative advanced practice nurse–led stroke treatment teams, with varying amounts of evidence available to provide direction. This article explores controversies associated with both approved and evolving treatments for ischemic and hemorrhagic stroke and makes recommendations for practice on the basis of the body of existing evidence, with an aim to improve the delivery of acute stroke treatment.
Arthroscopic Technique for Distal Tibial Allograft Bone Augmentation With Suture Anchor Fixation for Anterior Shoulder Instability
Tokish, John M. , Brinkman, Joseph C. , Hassebrock, Jeffrey D. , Hassebrock, Jeffrey D

Mayo Clinic

Arthroscopy Techniques | April 25, 2022 | Volume: 11 | Issue: 5 | Pages: No page available

10.1016/j.eats.2022.01.010 | PMID 35646558 Get It

Abstract Recurrent instability associated with glenoid bone loss is a commonly encountered problem after anterior shoulder dislocation. Surgical management with bony augmentation can be achieved with several allograft or autograft options. Fixation strategies also vary, including screw, suture button, or suture anchor fixation. Concerns exist regarding screw fixation because of the technical difficulty of a medial portal establishment, as well as the potential for graft osteolysis. Suture button fixation for osteochondral graft fixation has been previously described. However, no description of graft fixation using suture anchors exists. We describe an arthroscopic technique for glenoid augmentation using distal tibial allograft with suture anchor fixation. Technique Video video See video under supplementary data.
Ablation for oligometastatic colorectal carcinoma in extrahepatic, extrapulmonary sites
Thompson, Scott M. , Welch, Brian T. , Kurup, A. Nicholas , Kurup, A Nick, Kurup, Anil N

Mayo Clinic

International Journal of Hyperthermia | April 24, 2022 | Volume: 39 | Issue: 1 | Pages: 633-638

10.1080/02656736.2021.1952318 | PMID 35465801 Get It

IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma
Rechberger, Julian S. , Porath, Kendra A. , Zhang, Liang , Schrecengost, Randy S., Daniels, David J. , Nesvick, Cody L. , Daniels, David J , Rechberger, Julian S , Sarkaria, Jann N.

Mayo Clinic

Pharmaceutics | April 24, 2022 | Volume: 14 | Issue: 5 | Pages: 922

10.3390/pharmaceutics14050922 | PMID 35631512 Get It

High-grade gliomas (HGG) are devastating diseases in children and adults. In the pediatric population, diffuse midline gliomas (DMG) harboring H3K27 alterations are the most aggressive primary malignant brain tumors. With no effective therapies available, children typically succumb to disease within one year of diagnosis. In adults, glioblastoma (GBM) remains largely intractable, with a median survival of approximately 14 months despite standard clinical care of radiation and temozolomide. Therefore, effective therapies for these tumors remain one of the most urgent and unmet needs in modern medicine. Interleukin 13 receptor subunit alpha 2 (IL-13Rα2) is a cell-surface transmembrane protein upregulated in many HGGs, including DMG and adult GBM, posing a potentially promising therapeutic target for these tumors. In this study, we investigated the pharmacological effects of GB-13 (also known as IL13.E13K-PE4E), a novel peptide–toxin conjugate that contains a targeting moiety designed to bind IL-13Rα2 with high specificity and a point-mutant cytotoxic domain derived from Pseudomonas exotoxin A. Glioma cell lines demonstrated a spectrum of IL-13Rα2 expression at both the transcript and protein level. Anti-tumor effects of GB-13 strongly correlated with IL-13Rα2 expression and were reflected in apoptosis induction and decreased cell proliferation in vitro. Direct intratumoral administration of GB-13 via convection-enhanced delivery (CED) significantly decreased tumor burden and resulted in prolonged survival in IL-13Rα2-upregulated orthotopic xenograft models of HGG. In summary, administration of GB-13 demonstrated a promising pharmacological response in HGG models both in vitro and in vivo in a manner strongly associated with IL-13Rα2 expression, underscoring the potential of this IL-13Rα2-targeted therapy in a subset of HGG with increased IL-13Rα2 levels.